138.06 0.00 (0.00%)
After hours: 4:46PM EDT
|Bid||121.46 x 100|
|Ask||143.84 x 100|
|Day's Range||137.75 - 143.59|
|52 Week Range||46.90 - 153.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam dipped after partnering with Regeneron to research treatments for a form of nonalcoholic fatty liver disease.
Regeneron Pharmaceuticals (REGN) enters a collaboration with Alnylam to discover and develop RNAi-based therapies for treatment of NASH.
Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY): Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). On 31 December 2017, the US$14.81B market-cap posted aRead More...
Alnylam Pharmaceuticals (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets. The Analyst Chardan analyst Keay Nakae ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Cambridge, Massachusetts-based company said it had a loss of $1.48 per share. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
According to Sanofi’s (SNY) 2020 road map, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space. The company’s acquisition of Bioverativ (BIVV), which is aimed at expanding Sanofi’s leadership from genetic diseases into hemophilia, emphasizes this underlying goal.